Investors stayed bullish after the release, sending shares roughly 9% higher in early morning trade. Highlights from its update discussed the potentially transformative acquisition of RespRx from
Also catching a good amount of attention is the announcement that PAOG is working with Veristat, a contract research organization (CRO). That agreement is expected to leverage Veristat's expertise, which is dedicated to advancing clinical therapies and treatments through regulatory approval. PAOG is also expected to soon announce new breakthroughs in its CBD RespRx pharmaceutical research.
Other deals are earning attention as well.
Partnerships To Accelerate Commercialization
Last month, PAOG released a comprehensive update on its CBD Nutraceutical Development Program, saying that the first CBD nutraceutical product is expected to come to market before the end of the year. That effort is supported by
Now, with the run toward commercialization in play, investors are paying close attention to how PAOG can capitalize during the remainder of the year. Notably, investors appear to be investing ahead of the news, purchasing what they believe are significantly undervalued shares. In February, shares traded approximately 100% higher than current levels, and the information this morning could ignite a rally back toward those levels. Volume on Monday was substantial, with more than 47 million shares trading hands. Follow through today could indicate momentum is on PAOG's side.
Revenue Is A Defining Advantage For PAOG
Of interest as well is that PAOG is a generating company. That, in and of itself, could help drive share prices higher. PAOG said it expects to generate
In addition to revenues, many think that PAOG can benefit from consolidation in the sector. With JAZZ purchasing
Keep in mind that PAOG shares are higher by more than 385% YTD. Thus, the 21% gain on Monday only adds to an already staggering share price increase. Moreover, the rally started last week is news-based, and the update on Tuesday added fuel to the bullish premise that PAOG could deliver at least two catalysts later this year.
Better still, with two therapeutics in play, PAOG is ideally positioned to create shareholder value from partnerships and/or licensing agreements. In fact, with its drugs targeting billion-dollar markets, it's likely that as the company nears its planned commercialization that offers could be entertained. The patented extraction process could be the lynchpin in getting a deal done if they elect to go that route.
Clearly, investors are responding well to the company's developments. For a nano-cap stock,
With multiple shots on goal, having an agreement with a CRO, and partnerships that can accelerate product commercialization, PAOG is a small stock that could deliver massive rewards. This one is definitely ripe for consideration.
Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Hawk Point Media was compensated three-thousand-five-hundred-dollars by wire transfer to produce research, video, email, newsletters, and editorial commentary for
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company
Contact Person: KL Feigeles
Email: editorial@hawkpointmedia.com
City:
State:
Country:
Website: https://www.greenlightstocks.com
.
(C) 2021 M2 COMMUNICATIONS, source